David A. Sallman. To target the untargetable: elucidation of synergy of APR-246 and azacitidine in TP53 mutant myelodysplastic syndromes and acute myeloid leukemia. haematol [Internet]. 2020Jun.1 [cited 2024Apr.18];105(6):1470-2. Available from: https://haematologica.org/article/view/9419